Posts

Posted on

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

  • Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day
  • Approval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumps
  • Approval is supported by results from the Phase 3 INHALE–1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere® inhaled insulin development
  • Eligible patients can access Afrezza today for $35 or less per month, with dedicated support through MannKind Cares

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.

In the United States, more than 350,000 children and adolescents are living with diabetes, the majority of whom have type 1 diabetes and require lifelong insulin therapy. Afrezza delivers insulin into the bloodstream through the lungs using MannKind’s proprietary Technosphere® drug-delivery platform, enabling rapid absorption of insulin into systemic circulation. Afrezza is an ultra rapid-acting inhaled insulin taken when you eat that more closely mimics the body’s natural insulin response at mealtime.

“Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary,” said Desmond Schatz, Professor of Pediatrics, University of Florida College of Medicine. “With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option.”

This approval expands Afrezza’s availability beyond adults, introducing a new mealtime insulin option for pediatric patients and caregivers. The FDA approval is supported by results from the pivotal INHALE‑1 clinical trial, along with additional safety, efficacy, and long‑term exposure data from studies evaluating inhaled insulin over the past two decades of development.

“For more than a century, insulin therapy for children living with diabetes has largely meant multiple daily injections,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “Children and their families deserve new treatment options that fit the realities of daily life. Afrezza allows dosing at the moment of eating, without the need for pre-meal planning, making it a practical option for unplanned meals and snacks on the go. Our founder, Al Mann, would be proud of the dedication and teamwork that made it possible to bring this novel innovation to children and families.”

“For families raising children with diabetes, every day is shaped by treatment decisions – and those decisions are deeply personal,” said Jeff Hitchcock, Founder, President and CEO of Children With Diabetes. “Having navigated those choices firsthand for my own child, I understand that what works for one child may not work for another, and parents know this better than anyone. The approval of Afrezza for pediatric use represents a meaningful step forward for children and adolescents living with diabetes, and for the families who support, advocate, and care for them every single day. It adds an important new option to the diabetes toolkit and signals continued progress toward more individualized care for kids and teens.”

MannKind is committed to helping people access the medicines they are prescribed and minimizing barriers to care. Afrezza is now available for eligible patients for $35 or less/month, and MannKind Cares provides dedicated support for patients, caregivers and healthcare providers seeking access and coverage information at (844) 323-7399 (toll free).

About Afrezza

Afrezza® (pronounced uh-frezz-uh) Inhalation Powder is the only ultra rapid-acting inhaled insulin approved by the U.S. Food and Drug Administration to improve glycemic control in children, adolescent, and adult patients with diabetes mellitus. Administered at the beginning of meals using a small, portable inhaler, Afrezza delivers insulin via MannKind’s proprietary Technosphere® technology, enabling ultra-rapid absorption through the lungs. Afrezza has a fast onset of action and a short duration, more closely mirroring the body’s natural insulin response to meals. Afrezza was first approved by the FDA in June 2014 to improve glycemic control in adult patients (age 18+) with diabetes mellitus, followed by an additional FDA approval for use in pediatric patients (age 6 and older) in May 2026.

Important Safety Information

What is the most important information I should know about AFREZZA?
AFREZZA can cause serious side effects, including:

  • Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.

What is AFREZZA?

  • AFREZZA is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults and children 6 years of age and older, with diabetes mellitus.
  • AFREZZA is not for use to treat diabetic ketoacidosis. AFREZZA must be used with basal insulin in people who have type 1 diabetes mellitus.
  • It is not known if AFREZZA is safe and effective for use in people who smoke. AFREZZA is not for use in people who smoke or have recently stopped smoking (less than 6 months).
  • It is not known if AFREZZA is safe and effective in children under 6 years of age.

Who should not use AFREZZA?
Do not use AFREZZA if you:

  • Are having an episode of low blood sugar (hypoglycemia).
  • Have chronic lung problems such as asthma or COPD.
  • Are allergic to regular human insulin or any of the ingredients in AFREZZA.

What should I tell my healthcare provider before using AFREZZA?
Before using AFREZZA, tell your healthcare provider about all your medical conditions, including if you:

  • Have lung problems such as asthma or COPD
  • Have or have had lung cancer
  • Are using any inhaled medications
  • Smoke or have recently stopped smoking
  • Have kidney or liver problems
  • Are pregnant, planning to become pregnant, or are breastfeeding. AFREZZA may harm your unborn or breastfeeding baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.

Before you start using AFREZZA, talk to your healthcare provider about low blood sugar and how to manage it.

What should I avoid while using AFREZZA?
While using AFREZZA do not:

  • Drive or operate heavy machinery, until you know how AFREZZA affects you
  • Drink alcohol or use over-the-counter medicines that contain alcohol
  • Smoke

What are the possible side effects of AFREZZA?
AFREZZA may cause serious side effects that can lead to death, including:
See “What is the most important information I should know about AFREZZA?”

Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include:

  • Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.

Decreased lung function. Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it, and yearly after that.

Lung cancer. In studies of AFREZZA in people with diabetes, lung cancer occurred in a few more people who were taking AFREZZA than in people who were taking other diabetes medications. There were too few cases to know if lung cancer was related to AFREZZA. If you have lung cancer, you and your healthcare provider should decide if you should use AFREZZA.

Diabetic ketoacidosis. Talk to your healthcare provider if you have an illness. Your AFREZZA dose or how often you check your blood sugar may need to be changed.

Severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:

  • A rash over your whole body, trouble breathing, a fast heartbeat, or sweating.

Low potassium in your blood (hypokalemia).

Heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with AFREZZA may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with AFREZZA. Your healthcare provider should monitor you closely while you are taking TZDs with AFREZZA. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:

  • Shortness of breath, swelling of your ankles or feet, sudden weight gain.

Treatment with TZDs and AFREZZA may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.

Get emergency medical help if you have:

  • Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

The most common side effects of AFREZZA include:

  • Low blood sugar (hypoglycemia), cough, sore throat.

These are not all the possible side effects of AFREZZA. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088). 

Please See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use at Afrezza.com/safety.

About MannKind

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements about how Afrezza may help clinicians better match insulin therapy to daily life, and how Afrezza represents a meaningful step forward for children and teens with diabetes. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “may”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that products we commercialize may only achieve a limited degree of commercial success and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

AFREZZA, MANNKIND and TECHNOSPHERE are registered trademarks of MannKind Corporation.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f03226ab-008e-469b-b0ef-dea826bb2eab
https://www.globenewswire.com/NewsRoom/AttachmentNg/162f5fc2-d065-41d9-954f-b45b856ed9f2
https://www.globenewswire.com/NewsRoom/AttachmentNg/316f5791-ab91-4a94-a781-17197c9b0261



MannKind Contacts:

Media Relations:
Christie Iacangelo
(818) 292-3500
[email protected]

Investor Relations:
Kate Miranda
(617) 921-5461
[email protected]

Posted on

ATN International, Inc. to Present and Host 1×1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026 in New York

BEVERLY, Mass., May 29, 2026 (GLOBE NEWSWIRE) — ATN International, Inc. (“ATN”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ATNI), a leading provider of digital infrastructure and communications services, today announced that management will participate in the 16th Annual East Coast IDEAS Investor Conference at The Westin New York at Times Square on June 11, 2026.

ATN will host one-on-one investor meetings throughout the day, with their presentation scheduled from 2:00 – 2:35 p.m. Eastern Time. Naji Khoury, Chief Executive Officer, Carlos Doliogli, Chief Financial Officer, and Michele Satrowsky, Senior Vice President, Head of IR & Treasury will attend the conference on behalf of the Company. ATN’s presentation will be webcast live and can be accessed through the conference host’s main website at https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company’s website: http://ir.atni.com. To schedule a one-on-one meeting, please contact the Three Part Advisors conference team at [email protected] or (817) 769-2373.


About ATN

ATN International, Inc. (Nasdaq: ATNI), headquartered in Beverly, Massachusetts, is a leading provider of digital infrastructure and communications services for all. The Company operates in the United States and internationally, including the Caribbean region, with a focus on rural and remote markets with a growing demand for infrastructure investments. The Company’s operating subsidiaries today primarily provide: (i) advanced wireless and wireline connectivity to residential, business, and government customers, including a range of high-speed Internet and data services, fixed and mobile wireless solutions, and video and voice services; and (ii) carrier and enterprise communications services, such as terrestrial and submarine fiber optic transport, and communications tower facilities. For more information, please visit www.atni.com.


Company Contact:


Michele Satrowsky
SVP, Head of IR & Treasury
ATN International Inc.
[email protected]
Investor Relations Contact:


Joe Noyons or Kelley Buchhorn
Three Part Advisors, LLC
[email protected];
[email protected] 



Posted on

KIMPTON ASHBEL NEW YORK – PARK AVENUE REINTERPRETS THE CLASSIC MANHATTAN TOWNHOUSE THROUGH A DESIGN-LED LENS

PR Newswire

A historic 1928 Beaux-Arts landmark is transformed into a layered, residential-inspired retreat defined by bespoke craftsmanship, architectural intimacy, and playful refinement

NEW YORK, May 29, 2026 /PRNewswire/ — Kimpton Ashbel New York – Park Avenue, part of IHG Hotels & Resorts‘ luxury and lifestyle portfolio, has introduced a thoughtfully curated design narrative rooted in the enduring elegance of Park Avenue’s storied townhouses. Set within a restored 1928 Beaux-Arts building originally developed as the Doral Park Avenue Hotel, the property has 205 guest rooms and suites, many with sweeping views of Park Avenue and the Empire State Building and brings the warmth and character of a private residence into a refined hotel experience in Midtown Manhattan.

Designed by Busta Studio, the interiors draw from the scale and character of a classic New York townhouse, emphasizing material richness, artisanal detail, and a considered architectural approach. The guest experience begins at arrival, where the building’s carefully restored limestone façade and historic entry set the tone. Custom louvers at street level provide privacy steps away from Park Avenue while preserving natural light, reinforcing the feeling of an intimate urban retreat within the city. Within the building, the ground level lobby retains its original structure and proportions, subtly refreshed with reeded glass, warm wood floors, traditional rugs, and brass accents.

A custom inlaid mosaic featuring the property’s “K.A.” initials establish a strong sense of place from the outset. From there, the ground floor unfolds as a sequence of residential-style spaces rather than a conventional hotel lobby, transitioning naturally into a living room and family room connected through oversized wood portals that integrate preserved columns, original steps, and historic window openings. This architectural flow maintains the building’s historic integrity while creating an intimate, layered environment that encourages guests to slow down and settle in.

“Our approach was to treat Kimpton Ashbel as a true Park Avenue townhouse rather than a conventional hotel,” said Anna Busta, founder of Busta Studio. “We focused on proportion, materiality, and architectural detail to create spaces that feel layered and personal. The design is rooted in the building’s history, but intentionally relaxed, with moments of warmth and quiet surprise.”

Throughout the property, a restrained material palette of hand-brushed limed oak paneling, Bianco Dolomiti and Pietra marble, artisanal plaster ceilings, and hand-cast bronze and glass details create a calm architectural framework. Softer furnishings and subtle pops of color introduce warmth and personality, including jade green sofas in the lobby echoed in guestroom headboards for continuity.

At the heart of the building, the Living Room serves as an elegant gathering space designed for unhurried moments, featuring a sculptural floating banquette and a thoughtfully integrated library. Throughout the day, the hotel’s public spaces are animated by Kimpton’s signature social experiences, from the complimentary Kickstart coffee and tea each morning to Kimpton Social, the hosted evening gathering where guests are invited to enjoy curated selections of beer and wine.

Park & Bel, the hotel’s refined café concept, offers a carefully curated morning selection of artisanal pastries, seasonal fruit, and hearty sandwiches. As the day transitions into evening, the space takes on a more indulgent character, unveiling a bespoke bar cart in the evening hours. Featuring expertly curated cocktails and premium alcoholic offerings served alongside the café’s light fare, Park & Bel becomes an intimate yet vibrant destination, welcoming both hotel guests and locals to savor and linger.

Every element of Kimpton Ashbel is custom designed for the property, with particular attention given to the guestrooms as private extensions of the townhouse experience. Bespoke millwork, integrated headboards with built-in lighting and charging, and carefully proportioned furnishings create spaces that feel both residential and refined. In the guest bathrooms, custom-fitted cabinetry, carefully curated textiles, and thoughtfully selected finishes maximize comfort and functionality while maintaining the hotel’s cohesive design language. Specialty suites range from 14 family-friendly connecting rooms to the Penthouse Suite, which can be booked as a two-bedroom retreat with four bathrooms and two grand terraces.

Art is woven throughout public and private spaces. A site-specific collection curated by Soho Art Gallery features commissioned mixed-media works by Aida Subira, Natalie Ciccoricco, Robin Ahlgren and local artist Eric Blum. A curated library sourced from Assouline and Taschen adds further depth, reflecting interests spanning travel, architecture, fashion, and contemporary culture.

“With Kimpton Ashbel, our goal was to create a hotel that feels lived-in rather than staged,” said Sofia L. Vandaele, Regional Director of Operations for IHG Luxury & Lifestyle in New York. “The design encourages guests to slow down and settle in, whether that means relaxing in the lobby or retreating to a guestroom overlooking Park Avenue. We wanted the hotel to feel like a true extension of the neighborhood, offering warmth, ease, and a sense of belonging.”

With a unified design language carried throughout, Kimpton Ashbel New York – Park Avenue stands as a contemporary reinterpretation of the Manhattan townhouse, offering a thoughtfully crafted retreat that balances architectural integrity with the ease and warmth of residential living.

Kimpton Ashbel New York – Park Avenue is now accepting reservations. For more information, visit www.ashbelhotelnewyork.com.


About Kimpton Ashbel New York-Park Avenue

:

Kimpton Ashbel New York-Park Avenue recently debuted in Midtown Manhattan as one of the city’s newest Kimpton Hotels & Restaurants properties. Steps from Grand Central Station and surrounded by tree-lined streets, Gilded Age mansions, and classic architecture, the reimagined 1928 Beaux-Arts landmark features 205 stylish guestrooms and suites, many with sweeping views of Park Avenue and the Empire State Building.

Inspired by New York City’s iconic townhouses, the interiors balance elegance and modern sophistication with organic textures, light wood tones, and curated gold accents, creating a serene retreat in the heart of the city. At the center of the hotel, guests and locals can gather in the welcoming living room, anchored by Park & Bel, an innovative café concept, designed as a neighborhood favorite and must-visit for hotel guests, complemented by a thoughtfully curated bar cart experience.

Kimpton Ashbel New York-Park Avenue embodies the brand’s legacy of thoughtful hospitality, design-forward spaces, and a true sense of place in Midtown Manhattan. For more information, visit www.ashbelhotelnewyork.com.


About Kimpton

Kimpton, part of IHG Hotels & Resorts‘ luxury and lifestyle portfolio, pioneered the concept of hotels combining sophisticated, playful design with a more human guest experience in the U.S. Founded in 1981, the San Francisco-born luxury lifestyle brand now operates 83 properties and over 100 restaurants, bars and lounges across urban locations, resort destinations and up-and-coming markets globally. From inspiring design and expansive experiences to forward-thinking flavors that feed the soul, Kimpton spaces act as vibrant hubs for sparking authentic human connections. Every detail is thoughtfully curated and artfully delivered so that guest experiences remain meaningful, unscripted and inspired.

For more information, visit KimptonHotels.com.


About IHG Hotels & Resorts

IHG Hotels & Resorts (tickers: LON:IHG for Ordinary Shares; NYSE:IHG for ADRs) is a global hospitality company, with a purpose to provide True Hospitality for Good.

With a family of 20 hotel brands and IHG One Rewards, one of the world’s largest hotel loyalty programs with over 145 million members, IHG has more than one million rooms and 6,800 open hotels in over 100 countries, and a development pipeline of over 2,300 properties.

InterContinental Hotels Group PLC is the Group’s holding company and is incorporated and registered in England and Wales. Approximately 385,000 people work across IHG’s hotels and corporate offices globally. 

Visit us online for more about our hotels and reservations and IHG One Rewards. To download the IHG One Rewards app, visit the Apple App or Google Play stores.

For our latest news, visit our Newsroom and follow us on LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kimpton-ashbel-new-york—park-avenue-reinterprets-the-classic-manhattan-townhouse-through-a-design-led-lens-302785867.html

SOURCE Kimpton Ashbel New York – Park Avenue

Posted on

Sky Harbour to Present and Host Investor Meetings at the RBC Capital Markets Global Energy, Power & Infrastructure and at the Annual East Coast “IDEAS” Conference

Sky Harbour to Present and Host Investor Meetings at the RBC Capital Markets Global Energy, Power & Infrastructure and at the Annual East Coast “IDEAS” Conference

WEST HARRISON, N.Y.–(BUSINESS WIRE)–
Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, today announced that it will present and hold investor 1×1 meetings at the 2026 RBC Capital Markets Global Energy, Power & Infrastructure Conference (EPIC), on June 2–3, 2026 at the Westin Grand Central Hotel in New York, NY and the East Coast IDEAS Investor Conference on June 10–11, 2026 at the Westin Times Square Hotel in New York, NY.

The company will be presenting at an 8:00 am EST Breakout Session on Wednesday, June 3rd at the RBC Capital Markets Conference. If interested in participating or meeting with Sky Harbour management at the RBC Capital Markets Conference, please reach out to your RBC Capital Markets sales or wealth management representative.

The IDEAS Investor Conference presentation is webcast and can be accessed through the conference host’s main website: https://www.threepartadvisors.com/east-coast. If interested in participating or meeting with management in the IDEAS conference, please contact Lacey Wesley at [email protected].

About RBC EPIC

RBC Capital Markets’ Global Energy, Power & Infrastructure Conference (EPIC) is a long-standing, invitation-only forum that brings together executives and institutional investors from across the energy and utility value chain. Held annually in New York, the conference convenes participants spanning oil and gas producers, oilfield services, midstream, power and utilities, and infrastructure and energy transition, providing a venue to assess the opportunities and risks shaping the sector’s trajectory. The 2026 program is being held June 2–3 and is expected to focus on themes including energy security, rising power demand, infrastructure investment, grid modernization, natural gas growth, capital discipline, customer affordability, transition pragmatism, and cross-border trade resilience.

About IDEAS Investor Conferences

The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “SPONSORED BY INVESTORS. FOR INVESTORS.” and for the benefit of regional investment communities. Conference sponsors collectively have more than $200 billion in assets under management.

The IDEAS Investor Conferences are held annually and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com.

About Sky Harbour Group Corporation

Sky Harbour Group Corporation is an aviation infrastructure company developing the first nationwide network of Home-Basing campuses for business aircraft. The Company develops, leases and manages general aviation hangars across the United States. Sky Harbour’s Home-Basing offering aims to provide private and corporate customers with the best physical infrastructure in business aviation, coupled with dedicated service tailored to based aircraft, offering the shortest time to wheels-up in business aviation. To learn more, visit www.skyharbour.group.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements about the expectations regarding future operations at Sky Harbour Corporation and its subsidiaries. When used in this press release, the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on the current expectations of the management of Sky Harbour Group Corporation (the “Company”) as applicable and are inherently subject to uncertainties and changes in circumstances. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. For more information about risks facing the Company, see the Company’s annual report on Form 10-K for the year ended December 31, 2025, and other filings the Company makes with the SEC from time to time. The Company’s statements herein speak only as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SKYH Investor Relations:

[email protected]

Attn: Francisco X. Gonzalez, CFO

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance Air Transport Professional Services Building Systems Architecture Transportation Travel

MEDIA:

Logo
Logo
Posted on

Franklin Templeton Announces Availability of 19(a) Notices for Certain Closed-End Funds

Franklin Templeton Announces Availability of 19(a) Notices for Certain Closed-End Funds

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
The 19(a) monthly distribution notices for Templeton Emerging Markets Income Fund(NYSE: TEI) are now available. These informational notices provide further details on the sources of the funds’ monthly distributions and follow the most recent distribution announcement. The table below provides an estimate of the sources of the Fund’s current distribution and its cumulative distributions paid this fiscal year-to-date. Amounts are expressed on a per share of common stock basis, and as a percentage of the distribution amount.

 

 

 

Estimated sources & percentages of distributions

Ticker

Time period

Per share

distribution May

2026

Net

Investment

Income

Net realized

short-term

capital gains

Net realized

long-term

capital gains

Return of

Capital

TEI

Current

$0.0475

$0.0475

–

–

–

 

Month

 

100.0%

–

–

–

 

12/31

$0.2375

$0.1979

$0.0155

–

$0.0241

 

Fiscal YTD

 

83.3%

6.5%

–

10.2%

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

The table below provides information regarding total return performance for various periods through prior month end. Performance includes the deduction of management fees and administrative expenses, assumes reinvestment of distributions, and does not account for taxes. Fiscal YTD distribution rates are through the funds’ most recent distribution record date.

Annualized

Cumulative

Ticker

5-year average

annual total

return at NAV

Current

distribution rate

at NAV

Fiscal YTD

total return

at NAV

Fiscal YTD

distribution rate

at NAV

TEI (FYE 12/31)

6.47%

8.32%

 

4.00%

3.47%

NAV and total return performances are as of 4/30/26.

You should not draw any conclusions about a Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Distribution Policy.

Each fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’.

The Funds periodically provide fund-related information on their websites. The following information will be available for each Fund at www.franklintempleton.com at the frequencies indicated: (1) Full holdings will be available monthly; (2) Top 10 holdings and additional portfolio statistics will be available monthly.

INVESTMENT PRODUCTS: NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE

Copyright © 2026. Franklin Templeton. All rights reserved

Category: Distribution Related

Investor Contact: Fund Investor Services 1-888-777-0102

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Posted on

Franklin Templeton Announces Availability of 19(a) Notices for Certain Closed-End Funds

Franklin Templeton Announces Availability of 19(a) Notices for Certain Closed-End Funds

SAN MATEO, Calif.–(BUSINESS WIRE)–
The 19(a) monthly distribution notices for Franklin Limited Duration Income Trust (NYSE: FTF) are now available. These informational notices provide further details on the sources of the funds’ monthly distributions and follow the most recent distribution announcement. The table below provides an estimate of the sources of the Fund’s current distribution and its cumulative distributions paid this fiscal year-to-date. Amounts are expressed on a per share of common stock basis, and as a percentage of the distribution amount.

 

 

 

Estimated sources & percentages of distributions

Ticker

Time period

Per share

distribution May

2026

Net Investment

Income

Net realized

short-term

capital gains

Net realized

long-term

capital gains

Return of

Capital

FTF

Current

$0.0615

$0.0445

$0.0014

–

$0.0156

 

Month

 

72.3%

2.3%

–

25.4%

 

12/31

$0.3075

$0.2154

$0.0096

–

$0.0825

 

Fiscal YTD

 

70.1%

3.1%

–

26.8%

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

The table below provides information regarding total return performance for various periods through prior month end. Performance includes the deduction of management fees and administrative expenses, assumes reinvestment of distributions, and does not account for taxes. Fiscal YTD distribution rates are through the funds’ most recent distribution record date.

Annualized

Cumulative

Ticker

5-year average

annual total

return at NAV

Current

distribution rate

at NAV

 

Fiscal YTD

total return

at NAV

Fiscal YTD

distribution rate

at NAV

FTF (FYE 12/31)

2.98%

11.46%

 

1.02%

4.77%

NAV and total return performances are as of 4/30/26.

You should not draw any conclusions about a Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Distribution Policy.

Each fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’.

The Funds periodically provide fund-related information on their websites. The following information will be available for each Fund at www.franklintempleton.com at the frequencies indicated: (1) Full holdings will be available monthly; (2) Top 10 holdings and additional portfolio statistics will be available monthly.

INVESTMENT PRODUCTS: NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE

Copyright © 2026. Franklin Templeton. All rights reserved

Category: Distribution Related

Investor Contact: Fund Investor Services 1-888-777-0102

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

Stellantis N.V. (STLA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, May 29, 2026 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to Stellantis N.V. (“Stellantis” or the “Company”) (NYSE: STLA) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN STELLANTIS N.V. (STLA), CLICK

HERE
 BEFORE JUNE 8, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 

The complaint filed alleges that, between February 26, 2025 and February 5, 2026, Defendants failed to disclose to investors that: (1) the Company was not truly equipped or positioned to grow its adjusted operating income as forecasted; (2) the electrification market was either not truly growing as Defendants claimed or that Stellantis was not well positioned to capitalize upon it and convert the opportunity to growth; (3) Stellantis would ultimately be required to take on considerable charges to adjust its priority, focus, and overall execution in a shift away from BEV; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stellantis-nv-stla-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302785219.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Posted on

FS KKR Capital Corp. (FSK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, May 29, 2026 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to FS KKR Capital Corp. (“FS KKR Capital” or the “Company”) (NYSE: FSK) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FS KKR CAPITAL CORP. (FSK), CLICK

HERE
 BEFORE JULY 6, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 

The complaint filed alleges that, between May 8, 2024 and February 25, 2026, Defendants failed to disclose to investors: (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process; (3) the Company overstated the durability of its quarterly distribution strategy; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fs-kkr-capital-corp-fsk-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302785212.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Posted on

Sportradar Group AG (SRAD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

BENSALEM, Pa., May 29, 2026 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ: SRAD).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SPORTRADAR GROUP AG (SRAD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 17, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed alleges that, between November 7, 2024, and April 21, 2026, Defendants failed to disclose to investors that: (1) Sportradar intentionally worked with black-market gambling operators to increase its revenues, despite its assurances of strict legal and regulatory compliance and claims that ethics and integrity were crucial for Sportradar’s operations; (2) the Company’s KYC and compliance processes were not as robust as Defendants’ had claimed; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:  

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/sportradar-group-ag-srad-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302785222.html

SOURCE Law Offices of Howard G. Smith

Posted on

Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

BENSALEM, Pa., May 29, 2026 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JUNE 23, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed alleges that, between October 28, 2024 and October 31, 2025, Defendants failed to disclose to investors that: (1) Regencell was vulnerable and/or subject to market manipulation; (2) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; (3) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:  
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/regencell-bioscience-holdings-limited-rgc-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302785221.html

SOURCE Law Offices of Howard G. Smith